Literature DB >> 30090474

Pyrazinamide-induced hepatotoxicity and gender differences in rats as revealed by a 1H NMR based metabolomics approach.

He Zhao1, Zhi-Hong Si2, Ming-Hui Li1, Lei Jiang1, Yong-Hong Fu1, Yue-Xiao Xing1, Wei Hong1, Ling-Yu Ruan1, Pu-Ming Li1, Jun-Song Wang1.   

Abstract

Pyrazinamide (PZA) is a well-known first line anti-tuberculosis drug used in combination with other drugs such as isoniazid and rifampicin. Unfortunately, PZA suffered from a high rate of hepatotoxicity and hyperuricemia, which has not been clearly elucidated, hindering its wide application for therapeutic purposes. The purpose of this investigation was to develop a model of rat sub-acute hepatotoxicity induced by PZA and to explore the affected metabolic pathways by a 1H NMR-based metabolomics approach complemented with histopathological analysis and clinical chemistry. Rats of both genders were administered with PZA by gavage at doses of 1.0 and 2.0 g kg-1 for 4 weeks. PZA decreased the weights of dosed rats and induced liver injury dose-dependently. The female rats were more sensitive to PZA induced damage. Orthogonal signal correction partial least-squares discriminant analysis (OSC-PLS-DA) of the NMR profiles of the rat liver and serum revealed that PZA produced a status of oxidative stress and disturbances in purine metabolism, energy metabolism and NAD+ metabolism in a gender-specific and dose-dependent manner. These findings could be helpful to clarify the mechanism of PZA-induced hepatotoxicity and hyperuricemia. This integrated metabolomics approach showcased its ability to characterize the global metabolic status of organisms, providing a powerful and feasible tool to probe drug induced toxicity or side effects.

Entities:  

Year:  2016        PMID: 30090474      PMCID: PMC6062402          DOI: 10.1039/c6tx00245e

Source DB:  PubMed          Journal:  Toxicol Res (Camb)        ISSN: 2045-452X            Impact factor:   3.524


  47 in total

1.  Influence of L-tryptophan and its metabolites on gluconeogenesis in the isolated, perfused liver.

Authors:  C M Veneziale; P Walter; N Kneer; H A Lardy
Journal:  Biochemistry       Date:  1967-07       Impact factor: 3.162

2.  Isoniazid- and rifampicin-induced oxidative hepatic injury--protection by N-acetylcysteine.

Authors:  S Attri; S V Rana; K Vaiphei; C P Sodhi; R Katyal; R C Goel; C K Nain; K Singh
Journal:  Hum Exp Toxicol       Date:  2000-09       Impact factor: 2.903

3.  Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention.

Authors:  I M Weiner; J P Tinker
Journal:  J Pharmacol Exp Ther       Date:  1972-02       Impact factor: 4.030

4.  National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection.

Authors:  Peter D McElroy; Kashef Ijaz; Lauren A Lambert; John A Jereb; Michael F Iademarco; Kenneth G Castro; Thomas R Navin
Journal:  Clin Infect Dis       Date:  2005-09-09       Impact factor: 9.079

5.  NMR-based metabonomic analysis of the hepatotoxicity induced by combined exposure to PCBs and TCDD in rats.

Authors:  Chunfeng Lu; Yimei Wang; Zhiguo Sheng; Gang Liu; Ze Fu; Jing Zhao; Jun Zhao; Xianzhong Yan; Benzhan Zhu; Shuangqing Peng
Journal:  Toxicol Appl Pharmacol       Date:  2010-08-05       Impact factor: 4.219

6.  Phospholipid biosynthetic enzymes in human brain.

Authors:  B M Ross; A Moszczynska; J K Blusztajn; A Sherwin; A Lozano; S J Kish
Journal:  Lipids       Date:  1997-04       Impact factor: 1.880

7.  Hepatotoxicity of pyrazinamide: cohort and case-control analyses.

Authors:  Kwok C Chang; Chi C Leung; Wing W Yew; Tat Y Lau; Cheuk M Tam
Journal:  Am J Respir Crit Care Med       Date:  2008-04-03       Impact factor: 21.405

8.  Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.

Authors:  Rob van Hest; Hennie Baars; Sandra Kik; Paul van Gerven; Marie-Christine Trompenaars; Nico Kalisvaart; Sytze Keizer; Martien Borgdorff; Marlies Mensen; Frank Cobelens
Journal:  Clin Infect Dis       Date:  2004-07-30       Impact factor: 9.079

9.  Interaction between allopurinol and pyrazinamide.

Authors:  C Lacroix; C Guyonnaud; M Chaou; H Duwoos; O Lafont
Journal:  Eur Respir J       Date:  1988-10       Impact factor: 16.671

Review 10.  A world of cities and the end of TB.

Authors:  Amit Prasad; Alex Ross; Paul Rosenberg; Christopher Dye
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-03       Impact factor: 2.184

View more
  4 in total

1.  Metabolic Profiling of Bladder Cancer Patients' Serum Reveals Their Sensitivity to Neoadjuvant Chemotherapy.

Authors:  Juntao Zhuang; Xiao Yang; Qi Zheng; Kai Li; Lingkai Cai; Hao Yu; Jiancheng Lv; Kexin Bai; Qiang Cao; Pengchao Li; Haiwei Yang; Junsong Wang; Qiang Lu
Journal:  Metabolites       Date:  2022-06-17

2.  Early detection of metabolic changes in drug-induced steatosis using metabolomics approaches.

Authors:  Helena Y Yong; Gerald Larrouy-Maumus; Mire Zloh; Rosemary Smyth; Rayan Ataya; Christopher M Benton; Michael R Munday
Journal:  RSC Adv       Date:  2020-11-11       Impact factor: 4.036

3.  Growth inhibition and metabolomic analysis of Xanthomonas oryzae pv. oryzae treated with resveratrol.

Authors:  Huai-Zhi Luo; Ying Guan; Rui Yang; Guo-Liang Qian; Xian-Hui Yang; Jun-Song Wang; Ai-Qun Jia
Journal:  BMC Microbiol       Date:  2020-05-14       Impact factor: 3.605

4.  Neuroprotective effect and mechanism of baicalin on Parkinson's disease model induced by 6-OHDA.

Authors:  Li Tu; Zhuo-Yu Wu; Xiu-Lin Yang; Qian Zhang; Ran Gu; Qian Wang; Tian Tian; Huan Yao; Xiang Qu; Jin-Yong Tian
Journal:  Neuropsychiatr Dis Treat       Date:  2019-12-31       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.